Treasurer of the State of North Carolina Acquires 290 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Treasurer of the State of North Carolina boosted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 0.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 45,260 shares of the biopharmaceutical company’s stock after buying an additional 290 shares during the period. Treasurer of the State of North Carolina’s holdings in Intra-Cellular Therapies were worth $3,780,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of ITCI. GAMMA Investing LLC boosted its position in Intra-Cellular Therapies by 46.3% during the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 240 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in shares of Intra-Cellular Therapies in the 4th quarter valued at about $96,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Intra-Cellular Therapies in the 3rd quarter worth approximately $97,000. Barlow Wealth Partners Inc. bought a new position in shares of Intra-Cellular Therapies during the 4th quarter worth approximately $184,000. Finally, R Squared Ltd purchased a new stake in Intra-Cellular Therapies during the fourth quarter valued at approximately $205,000. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Price Performance

NASDAQ ITCI opened at $131.87 on Wednesday. Intra-Cellular Therapies, Inc. has a 1 year low of $64.09 and a 1 year high of $131.98. The company has a market capitalization of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. The company has a fifty day moving average of $130.48 and a 200 day moving average of $104.97.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The company had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. Research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on ITCI shares. Baird R W downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. StockNews.com started coverage on Intra-Cellular Therapies in a research note on Sunday. They issued a “hold” rating for the company. Royal Bank of Canada restated a “sector perform” rating and set a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $132.00 price objective on shares of Intra-Cellular Therapies in a research report on Wednesday, April 2nd. Finally, Mizuho downgraded shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $140.00 to $132.00 in a research report on Monday, February 24th. Eleven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Intra-Cellular Therapies currently has an average rating of “Hold” and a consensus target price of $106.23.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.